HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE

Ann Rheum Dis. 2014 Oct;73(10):1888-97. doi: 10.1136/annrheumdis-2013-203794. Epub 2013 Jul 29.

Abstract

Objective: Accumulation of mitochondria underlies T-cell dysfunction in systemic lupus erythematosus (SLE). Mitochondrial turnover involves endosomal traffic regulated by HRES-1/Rab4, a small GTPase that is overexpressed in lupus T cells. Therefore, we investigated whether (1) HRES-1/Rab4 impacts mitochondrial homeostasis and (2) Rab geranylgeranyl transferase inhibitor 3-PEHPC blocks mitochondrial accumulation in T cells, autoimmunity and disease development in lupus-prone mice.

Methods: Mitochondria were evaluated in peripheral blood lymphocytes (PBL) of 38 SLE patients and 21 healthy controls and mouse models by flow cytometry, microscopy and western blot. MRL/lpr mice were treated with 125 μg/kg 3-PEHPC or 1 mg/kg rapamycin for 10 weeks, from 4 weeks of age. Disease was monitored by antinuclear antibody (ANA) production, proteinuria, and renal histology.

Results: Overexpression of HRES-1/Rab4 increased the mitochondrial mass of PBL (1.4-fold; p=0.019) and Jurkat cells (2-fold; p=0.000016) and depleted the mitophagy initiator protein Drp1 both in human (-49%; p=0.01) and mouse lymphocytes (-41%; p=0.03). Drp1 protein levels were profoundly diminished in PBL of SLE patients (-86±3%; p=0.012). T cells of 4-week-old MRL/lpr mice exhibited 4.7-fold over-expression of Rab4A (p=0.0002), the murine homologue of HRES-1/Rab4, and depletion of Drp1 that preceded the accumulation of mitochondria, ANA production and nephritis. 3-PEHPC increased Drp1 (p=0.03) and reduced mitochondrial mass in T cells (p=0.02) and diminished ANA production (p=0.021), proteinuria (p=0.00004), and nephritis scores of lupus-prone mice (p<0.001).

Conclusions: These data reveal a pathogenic role for HRES-1/Rab4-mediated Drp1 depletion and identify endocytic control of mitophagy as a treatment target in SLE.

Keywords: Autoimmune Diseases; Autoimmunity; Systemic Lupus Erythematosus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autophagy / physiology
  • Case-Control Studies
  • Cells, Cultured
  • Diphosphonates / therapeutic use
  • Dynamins / blood
  • Dynamins / physiology
  • Female
  • GTP Phosphohydrolases / blood*
  • GTP Phosphohydrolases / physiology
  • Homeostasis / physiology
  • Humans
  • Jurkat Cells
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / immunology
  • Lysosomes / metabolism
  • Mice, Inbred MRL lpr
  • Microtubule-Associated Proteins / blood*
  • Microtubule-Associated Proteins / physiology
  • Mitochondria / metabolism*
  • Mitochondrial Proteins / blood*
  • Mitochondrial Proteins / physiology
  • Mitophagy / immunology
  • Molecular Targeted Therapy / methods
  • Pyridines / therapeutic use
  • T-Lymphocytes / metabolism
  • rab4 GTP-Binding Proteins / physiology*

Substances

  • 2-(3-pyridinyl)-1-hydroxyethylidene-1,1-phosphonocarboxylic acid
  • Diphosphonates
  • Microtubule-Associated Proteins
  • Mitochondrial Proteins
  • Pyridines
  • GTP Phosphohydrolases
  • rab4 GTP-Binding Proteins
  • DNM1L protein, human
  • Dnm1l protein, mouse
  • Dynamins